Navigation Links
Tigermed Sets Up Subsidiary, Hunan Tigermed Xiangya Drug R&D Ltd (Tigermed Xiangya)
Date:12/1/2008

HANGZHOU, China, Dec. 1 /PRNewswire-Asia/ -- Tigermed Consulting Co., Ltd, a leading Contract Research Organization (CRO) in China, announced that it has established a subsidiary, Hunan Tigermed Xiangya Drug R&D Ltd, with Central South University (CSU). The establishment of Tigermed Xiangya marks Tigermed's participation in the construction of a nationwide first-rate Phase I Clinical Laboratory, and further substantiates Tigermed's service ability in drug pre-clinical studies and pharmaceutical analysis. This new cooperation allows Tigermed to provide more extensive and comprehensive outsourcing clinical services for Multinational Pharmaceutical Corporations and Local Research Institutions in the research and development of innovative drugs.

Tigermed, staffed with a team of 100 plus professionals, is dedicated to providing such all-round services as Phase I-IV clinical trials, data management & statistical analysis and regulatory affairs, and Tigermed has accumulated outstanding experience in the clinical trials of innovative drugs. In July 2008, financed by Qiming Ventures, an internationally renowned venture capital organization, Tigermed entered into a period of rapid expansion.

Xiangya Medical College, predecessor of Xiangya Medical School of CSU, was founded in 1914 as one of the early western medicine colleges and universities in China, and enjoyed a high reputation as "South Xiangya, North Union", widely recognizing that Xiangya Medical College in the south and Peking Union Medical College in the north of China are the most two famous medical institutions. Currently, Xiangya Medical School of CSU has three affiliated tertiary hospitals, 8 clinical colleges and 24 stable teaching bases. Phase I Clinical Laboratory of the Drug Clinical Trial Agency in the third Xiangya Hospital of CSU is one of the first groups of Laboratories passing preliminary examination.

Tigermed Xia
'/>"/>

SOURCE China Medicine Corporation
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2

Related biology technology :

1. A Better Tomorrow Treatment Center Inc., Forterus Inc.s Behavioral Healthcare Subsidiary, is the First in the Nation to Offer DNA-Customized Treatment for Individuals with a Genetic Predisposition for Addictive Behavior
2. Nastech Assigns Intellectual Property Related to the Development of RNA-Based Therapeutics to its Subsidiary, MDRNA, Inc.
3. Mylan Inc. Subsidiary, Dey, L.P., Announces that Perforomist(TM) (Formoterol Fumarate) Inhalation Solution is Now Available for Maintenance Treatment of COPD
4. Viragen Internationals Subsidiary, ViraNative AB, Files to Seek Bankruptcy Protection in Sweden
5. Haemonetics Announces New Subsidiary, Haemonetics Software Solutions

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:11/30/2009)...AM, November 30 Biopharmaceutical ...st patients have been enrolled in its,multinationa...tudy is,designed to show reduction in transplant r... allogeneic stem cell transplantation with a misma...ents eligible for an allogeneic,stem cell transpla...
(Date:11/30/2009)...., Nov. 30 BioMarin Phar...hat the Food and Drug Administration (FDA) has gra...ne (3,4-DAP), amifampridine phosphate, for the rar...rome (LEMS). 3,4-DAP has previously received orph...2009, the Committee for Medicinal Products for Hum...
(Date:11/30/2009)...NGHAI, Nov. 30 /PRNewswire-Asia/ -- WuXi PharmaTec...nology, and medical-device research and,developmen... the United States,announced that it had been sel...9 list for the fifth consecutive year. The list re...,s technology, media, and telecommunications,indus...
(Date:11/28/2009)... The Vanuatu National Advisory Committee on Clima...unication (SNC) Project in collaboration with the ...d. of New Zealand have generated preliminary clima...m the background for the country’s SNC repor... Climate Change (UNFCCC). , ...
Breaking Biology Technology:Kiadis Pharma Announces Enrollment of First Patients in a Multinational Registration Study for ATIR(TM) 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 2FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 3FDA Grants Orphan Drug Designation for 3,4-DAP for LEMS 4WuXi PharmaTech Named in Deloitte Technology Fast 50 China 2009 List for the Fifth Consecutive Year 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 2Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 3Preliminary Climate and Sea Level Changes for Vanuatu Through the Application of SimCLIM 4
...ipitor Will Cause Market Share of Statins to, Drop...m Decision Resources, WALTHAM, Mass., Sept. 11 D...arch and advisory firms for pharmaceutical and,hea...el angiogenic agents,including a future blockbuste...ic treatment of peripheral arterial disease (PAD)....
... Track for Initiation Later This Year - - Confer... Time -, SAN DIEGO, Sept. 11 Arena Pharmaceutica...ndependent Echocardiographic,Data Safety Monitorin...op,the ongoing pivotal Phase 3 trial, BLOOM (Behav...nd Obesity Management). The BLOOM trial is,evaluat...
... in Atrial Fibrillation, EP Mapping and ... ST. LOUIS, Sept. 11 Stereotaxis, Inc.,(Nasdaq: ...dures have been,performed using the Stereotaxis sy...gnet-guided navigational technology intended to he...mplex arrhythmias and,perform other interventional...
Other Biology Technology:Novel Angiogenic Drugs, Including a Future Blockbuster from Genzyme, Could Revolutionize Treatment of Peripheral Arterial Disease 2Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 2Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 3Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 4Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 5Arena Pharmaceuticals Continues Phase 3 BLOOM Obesity Trial Following Independent Echocardiogaphic Data Safety Monitoring Board Review 6Stereotaxis' Niobe System Used to Perform More Than 10,000 Procedures Worldwide 2Stereotaxis' Niobe System Used to Perform More Than 10,000 Procedures Worldwide 3
(Date:11/30/2009)..., CLEMSON Clemson University researchers Ron Fal...ironmental Protection Agency grant to study the sa...ons located deep below the earth,s surface. , Wi...els believed to be the leading cause of global war...st promising alternatives for reducing emissions u...
(Date:11/30/2009)... This release is available in German . , T...llaborative Research Centres as of 1 January 2010....rants Committee in Bonn. The new centres will init... million. In addition, 20 percent overhead funding... project. The centres, research topics range from ...
(Date:11/30/2009)... The Editors of The Journal of Experimental Biolo...from Centre National de la Recherche Scientifique ...s the winner of this year,s JEB Outstanding Pape...n outstanding achievement and is intended to encou...JEB Editor-in-Chief, and adds that ,we truly appr...
Breaking Biology News(10 mins):DFG approves funding for 17 new collaborative research centers 2DFG approves funding for 17 new collaborative research centers 3DFG approves funding for 17 new collaborative research centers 4DFG approves funding for 17 new collaborative research centers 5DFG approves funding for 17 new collaborative research centers 6DFG approves funding for 17 new collaborative research centers 7DFG approves funding for 17 new collaborative research centers 8DFG approves funding for 17 new collaborative research centers 9French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 2French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 3French scientist wins the Journal of Experimental Biology Outstanding Paper Prize 2009 4Inhibikase Therapeutics Discusses New Platform for Infectious Disease Pharmaceuticals at BIOCOM 2009 5678 1Physical scientists at Arizona State University will apply laws of physics in cancer fight 60067 1Physical scientists at Arizona State University will apply laws of physics in cancer fight 60067 2Physical scientists at Arizona State University will apply laws of physics in cancer fight 60067 3Physical scientists at Arizona State University will apply laws of physics in cancer fight 60067 4Chemosensitivity of cancer cells depends on their protein dependency 10521 1Chemosensitivity of cancer cells depends on their protein dependency 10521 2
...sed to detect chemical warfare agents and explosiv...ty of Manchester to treat hospital patients with l...chers are using a sensor, commonly used to detect ...agnosing lung disease. , The microDMx TM sensor,... develop a new technique which is able to detect ,...
...rotein most commonly used in the world for therape...e and to avoid risk of a heart attack, its adminis... occurrence. It is used for haemorrhages, burns, s...oms of malnutrition or dehydration, chronic infect...umption in Spain is about 10 tons but, at a worldw...
...forest might not have yielded pots of gold, but it...ne: some of the globe,s richest soil that can tran...,s not all. Scientists have a method to reproduce ...rk earths -- and say it can pull substantial amoun...n dioxide in the Earth,s atmosphere, helping to pr...
Other Biology News:Chemical warfare agent detection technology used to treat lung disease 2Human albumin from tobacco plants 2Human albumin from tobacco plants 3GPSDB, the free Gene and Protein Synonyms DataBase 2
Chicken Anti-Human DCTD Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-Cow Xanthine Oxidase Polyclonal Antibody, HRP Conjugated from Abcam
Chicken Anti-Human LYZL6 Polyclonal Antibody, Unconjugated from Abcam
Rabbit Anti-UBC12 Polyclonal Antibody, Unconjugated from Abcam
Biology Products: